Literature DB >> 23983891

Glucocorticoids: complications to anticipate and prevent.

Lianne S Gensler1.   

Abstract

Glucocorticoids (GCs) are widely used for inflammatory and autoimmune diseases. Their mechanism of action is most commonly rooted in genomic effects that have both beneficial and adverse consequences. The purpose of this review is to discuss the potential complications and side effects that may occur with GC use. Many of these complications are related to the dose and duration of therapy used. Evidence-based preventative strategies are discussed. Many recommendations are based on expert opinion and not on strong evidence. A 54-year-old man presents with proximal upper and lower extremity weakness. There are no rashes. The antinuclear antibody is negative; the erythrocyte sedimentation rate and C reactive protein are 24 mm/h and 3 mg/dL, respectively. An electromyography displays myopathic motor unit potentials with fibrillation and a muscle biopsy confirms polymyositis. Prednisone of 60 mg/d is initiated. What are the risks associated with GC use? What other studies and interventions should occur in this patient starting long-term GC therapy?

Entities:  

Keywords:  autoimmune diseases of the nervous system; central nervous system; clinical specialty; myositis; neuromuscular diseases; rheumatology; vasculitis

Year:  2013        PMID: 23983891      PMCID: PMC3726115          DOI: 10.1177/1941874412458678

Source DB:  PubMed          Journal:  Neurohospitalist        ISSN: 1941-8744


  55 in total

1.  Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice.

Authors:  M C van der Goes; J W G Jacobs; M Boers; T Andrews; M A M Blom-Bakkers; F Buttgereit; N Caeyers; M Cutolo; J A P Da Silva; L Guillevin; J R Kirwan; J Rovensky; G Severijns; S Webber; R Westhovens; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2010-08-06       Impact factor: 19.103

2.  EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.

Authors:  J N Hoes; J W G Jacobs; M Boers; D Boumpas; F Buttgereit; N Caeyers; E H Choy; M Cutolo; J A P Da Silva; G Esselens; L Guillevin; I Hafstrom; J R Kirwan; J Rovensky; A Russell; K G Saag; B Svensson; R Westhovens; H Zeidler; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2007-07-27       Impact factor: 19.103

3.  Corticosteroids and the risk of atrial fibrillation.

Authors:  Cornelis S van der Hooft; Jan Heeringa; Guy G Brusselle; Albert Hofman; Jacqueline C M Witteman; J Herre Kingma; Miriam C J M Sturkenboom; Bruno H Ch Stricker
Journal:  Arch Intern Med       Date:  2006-05-08

4.  Suicidality and corticosteroid-induced psychosis.

Authors:  P Bräunig; J Bleistein; M L Rao
Journal:  Biol Psychiatry       Date:  1989-06       Impact factor: 13.382

5.  Complications of long-term steroid therapy for asthma.

Authors:  P Lieberman; R Patterson; R Kunske
Journal:  J Allergy Clin Immunol       Date:  1972-06       Impact factor: 10.793

6.  Initial functional status predicts infections during steroid therapy for renal diseases.

Authors:  Y Sakuma; T Katoh; K Owada; H Suzuki; K Sakurai; M Eiro; K Asahi; T Watanabe
Journal:  Clin Nephrol       Date:  2005-02       Impact factor: 0.975

Review 7.  Steroid psychosis: a review.

Authors:  François Sirois
Journal:  Gen Hosp Psychiatry       Date:  2003 Jan-Feb       Impact factor: 3.238

Review 8.  Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials.

Authors:  Hefziba Green; Mical Paul; Liat Vidal; Leonard Leibovici
Journal:  Mayo Clin Proc       Date:  2007-09       Impact factor: 7.616

9.  Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature.

Authors:  D A Lewis; R E Smith
Journal:  J Affect Disord       Date:  1983-11       Impact factor: 4.839

10.  Prednisone effects on neurochemistry and behavior. Preliminary findings.

Authors:  O M Wolkowitz; D Rubinow; A R Doran; A Breier; W H Berrettini; M A Kling; D Pickar
Journal:  Arch Gen Psychiatry       Date:  1990-10
View more
  18 in total

1.  Methylprednisolone acetate mitigates IL1β induced changes in matrix metalloproteinase gene expression in skeletally immature ovine explant knee tissues.

Authors:  Kristen I Barton; May Chung; Cyril B Frank; Nigel G Shrive; David A Hart
Journal:  Inflamm Res       Date:  2020-11-23       Impact factor: 4.575

2.  Location and gene-specific effects of methylprednisolone acetate on mitigating IL1β-induced inflammation in mature ovine explant knee tissue.

Authors:  Kristen I Barton; Bryan J Heard; May Chung; Johnathan L Sevick; C Ryan Martin; Yamini Achari; Cyril B Frank; Nigel G Shrive; David A Hart
Journal:  Inflamm Res       Date:  2016-11-16       Impact factor: 4.575

Review 3.  Asthma and Corticosteroid Responses in Childhood and Adult Asthma.

Authors:  Amira Ali Ramadan; Jonathan M Gaffin; Elliot Israel; Wanda Phipatanakul
Journal:  Clin Chest Med       Date:  2019-03       Impact factor: 2.878

4.  Modulation of the oral glucocorticoid system during black raspberry mediated oral cancer chemoprevention.

Authors:  Divya Nedungadi; Nathan Ryan; Kelvin Anderson; Felipe F Lamenza; Pete P Jordanides; Michael J Swingler; Liva Rakotondraibe; Kenneth M Riedl; Hans Iwenofu; Steve Oghumu
Journal:  Carcinogenesis       Date:  2022-02-11       Impact factor: 4.944

5.  Use of inhaled corticosteroids and risk of acquiring Pseudomonas aeruginosa in patients with chronic obstructive pulmonary disease.

Authors:  Josefin Eklöf; Truls Sylvan Ingebrigtsen; Rikke Sørensen; Mohamad Isam Saeed; Imane Achir Alispahic; Pradeesh Sivapalan; Jonas Bredtoft Boel; Jette Bangsborg; Christian Ostergaard; Ram Benny Dessau; Ulrich Stab Jensen; Ejvind Frausing Hansen; Therese Sophie Lapperre; Howraman Meteran; Torgny Wilcke; Niels Seersholm; Jens-Ulrik Stæhr Jensen
Journal:  Thorax       Date:  2021-08-26       Impact factor: 9.102

6.  Use of Inhaled Corticosteroids and Risk of Acquiring Haemophilus influenzae in Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Raza Ul Mohsin; Christian Kjer Heerfordt; Josefin Eklöf; Pradeesh Sivapalan; Mohamad Isam Saeed; Truls Sylvan Ingebrigtsen; Susanne Dam Nielsen; Zitta Barrella Harboe; Kasper Karmark Iversen; Jette Bangsborg; Jens Otto Jarløv; Jonas Bredtoft Boel; Christian Østergaard Andersen; Henrik Pierre Calum; Ram B Dessau; Jens-Ulrik Stæhr Jensen
Journal:  J Clin Med       Date:  2022-06-20       Impact factor: 4.964

7.  A clinically relevant decrease in contractile force differentially regulates control of glucocorticoid receptor translocation in mouse skeletal muscle.

Authors:  Kirsten R Dunlap; Jennifer L Steiner; Michael L Rossetti; Scot R Kimball; Bradley S Gordon
Journal:  J Appl Physiol (1985)       Date:  2021-02-18

Review 8.  The Use of the Anticoagulant Heparin and Corticosteroid Dexamethasone as Prominent Treatments for COVID-19.

Authors:  Heloísa Antoniella Braz-de-Melo; Sara Socorro Faria; Gabriel Pasquarelli-do-Nascimento; Igor de Oliveira Santos; Gary P Kobinger; Kelly Grace Magalhães
Journal:  Front Med (Lausanne)       Date:  2021-04-23

9.  Serum metabolomic response of myasthenia gravis patients to chronic prednisone treatment.

Authors:  Manjistha Sengupta; Amrita Cheema; Henry J Kaminski; Linda L Kusner
Journal:  PLoS One       Date:  2014-07-17       Impact factor: 3.240

10.  Solid Lipid Nanoparticles Loaded with Glucocorticoids Protect Auditory Cells from Cisplatin-Induced Ototoxicity.

Authors:  Blanca Cervantes; Lide Arana; Silvia Murillo-Cuesta; Marina Bruno; Itziar Alkorta; Isabel Varela-Nieto
Journal:  J Clin Med       Date:  2019-09-14       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.